and as a primary HCV receptor that interacts with the virus envelope proteins (anti-SR-BI mAbs, BLT-2, -3 and -4, ITX-5061, ITX-7650, rimcazole); Another cholesterol uptake receptor, NPC1L1 ...

Ideally, entry inhibitors block viral binding to the host (co)receptors without affecting their physiological function. Presumably, future anti-HCV therapies will be combinations of drugs ...

In a new clinical practice guideline, the AGA provided evidence-based recommendations for either antiviral prophylaxis or continued surveillance to manage hepatitis B virus reactivation in patients ...